Drug intelligence / Profile preview

ARRY-768

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

ARRY-768 is an Array BioPharma-originated, orally active small-molecule inhibitor of platelet-derived growth factor receptors. In preclinical dermal-fibrosis models relevant to systemic sclerosis, it inhibited PDGFR signaling and reduced fibrosis, including regression of established bleomycin-induced dermal fibrosis; the reported PDGFR inhibitory potency was greater than that of imatinib in the cited comparison. ([ard.bmj.com](https://ard.bmj.com/content/71/Suppl_3/479.2))

Targets

PDGFR (PDGFR family)

Beyond the preview

Go deeper on ARRY-768.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARRY-768.

Explore the full profile